查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602824

抗糖尿病藥物市場：按類型、疾病、患者分類 - 全球預測 2025-2030

Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年抗糖尿病藥物市值為469.3億美元，預計2024年將達到514.2億美元，複合年成長率為10.14%，到2030年將達到923.2億美元。

抗糖尿病藥物市場主要集中在透過控制血糖值來控制糖尿病（主要是第 1 型和第 2 型糖尿病）的藥物。該市場包括多種藥物類別，包括胰島素製劑、雙胍類、磺醯尿素、DPP-4抑制劑、GLP-1受體促效劑和SGLT2抑制劑。這些藥物的需求源自於人口老化、生活方式改變、肥胖和遺傳因素引起的全球糖尿病流行。由於發病率增加以及需要有效的疾病管理以預防神經病變、視網膜病變和心血管疾病等併發症，藥物治療仍然至關重要。最終用途主要是在醫院、診所和居家照護中，隨著患者在疾病管理方面的能力增強，應用範圍也在擴大。

主要市場統計
基準年[2023] 469.3億美元
預測年份 [2024] 514.2億美元
預測年份 [2030] 923.2億美元
複合年成長率（%） 10.14%

關鍵的成長要素包括給藥系統的技術進步、研發投資的增加以及支持糖尿病管理計畫的有利政府政策。治療機會包括更加關注個人化醫療、開發具有更高療效和更少副作用的新型抗糖尿病藥物的市場開拓，以及擴展到擁有支持糖尿病治療的已開發醫療基礎設施的新興市場。然而，市場開拓受到高昂的藥物開發成本、嚴格的監管核准以及生活方式改變和減肥手術等替代療法的競爭的限制。此外，在許多低收入者居住的地區，負擔能力和可用性也是問題。

創新將致力於開發同時控制糖尿病和METABOLIC INC.症候群的口服胰島素和混合藥物。基因療法和微生物影響的糖尿病治療的研究也很有希望。市場是動態的，受到持續的技術創新和滿足未滿足需求的競爭策略的驅動。策略重點是與高科技公司合作，將人工智慧和物聯網整合到糖尿病管理系統中，可以提高患者的依從性和治療結果，並推動業務的顯著成長。尋找生物相似藥和具有成本效益的學名藥也可能帶來巨大的市場機會，特別是在價格敏感的市場。

市場動態：揭示快速發展的抗糖尿病市場的關鍵市場洞察

供需因素的動態交互作用正在改變抗糖尿病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 人類糖尿病和肥胖症盛行率不斷增加
    • 提高患者和醫療保健專業人員對糖尿病管理重要性的認知
    • 支持糖尿病意識和治療的措施和計劃
  • 市場限制因素
    • 與抗糖尿病藥物相關的副作用
  • 市場機會
    • 持續研發抗糖尿病新藥
    • 透過政府和私人公司合作供應廉價藥品
  • 市場挑戰
    • 抗糖尿病藥物核准的嚴格監管要求

波特五力：駕馭抗糖尿病市場的策略工具

波特的五力框架是了解抗糖尿病藥物市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解抗糖尿病市場的外部影響

外部宏觀環境因素在塑造抗糖尿病藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解抗糖尿病藥物市場的競爭狀況

抗糖尿病藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣抗糖尿病藥物市場供應商的績效評估

FPNV定位矩陣是評估抗糖尿病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議描繪抗糖尿病藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，抗糖尿病藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 糖尿病和肥胖症盛行率不斷上升
      • 提高病人和醫護人員對糖尿病管理重要性的認知
      • 支持糖尿病意識和治療的措施和計劃
    • 抑制因素
      • 與抗糖尿病藥物相關的不良反應
    • 機會
      • 新型抗糖尿病藥物的研發正在進行中
      • 政府和私人公司合作提供廉價藥品
    • 任務
      • 抗糖尿病藥物核准有嚴格監管要求
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章抗糖尿病藥物市場：依類型

  • α葡萄Glucosidase抑制劑
  • 雙胍
  • DPP-IV（Dipeptidyl Peptidase）抑制劑
  • GLP-1（類升糖素肽）促效劑
  • 胰島素
    • 中效胰島素
    • 長效類似物
    • 混合胰島素
    • 快速反應模擬
    • 短效類似物
  • Meglitinides
  • SGLT-II（鈉葡萄糖轉運蛋白）​​抑制劑
  • 磺醯尿素類
  • 胰島素增敏劑

第7章 抗糖尿病藥物市場：依疾病分類

  • 1型糖尿病
  • 2型糖尿病

第8章按患者分類的抗糖尿病藥物市場

  • 成人用
  • 老年病
  • 小兒科

第9章北美和南美抗糖尿病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太抗糖尿病市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲抗糖尿病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
Product Code: MRR-437896AA366F

The Antidiabetic Drugs Market was valued at USD 46.93 billion in 2023, expected to reach USD 51.42 billion in 2024, and is projected to grow at a CAGR of 10.14%, to USD 92.32 billion by 2030.

The antidiabetic drugs market is centered around medications used to manage diabetes, primarily type 1 and type 2 diabetes, by controlling blood glucose levels. This market encompasses a wide array of drug classes including insulin, biguanides, sulfonylureas, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. The necessity of these drugs arises from the global prevalence of diabetes, driven by aging populations, lifestyle changes, obesity, and genetic factors. Pharmacological therapy remains essential due to these escalating incidences and the need for effective disease management to prevent complications such as neuropathy, retinopathy, and cardiovascular issues. The application is vast, with end-use primarily in hospitals, clinics, and homecare settings as patient empowerment in disease management increases.

KEY MARKET STATISTICS
Base Year [2023] USD 46.93 billion
Estimated Year [2024] USD 51.42 billion
Forecast Year [2030] USD 92.32 billion
CAGR (%) 10.14%

Key growth factors include technological advancements in drug delivery systems, increasing investment in R&D, and favorable governmental policies supporting diabetes management programs. Opportunities arise from the growing focus on personalized medicine, the development of new classes of antidiabetic drugs with improved efficacy and fewer side effects, and the expansion into emerging markets where rising healthcare infrastructure supports diabetes treatment. Nonetheless, market growth faces limitations from high drug development costs, stringent regulatory approvals, and competition with alternative therapies like lifestyle modification and bariatric surgery. Challenges also include affordability and accessibility in low-income regions.

Innovation can be directed towards developing oral insulin and hybrid drugs that control both diabetes and metabolic syndromes simultaneously. Research into gene therapy and microbiome-influenced diabetes treatment also holds promise. The market is dynamic, driven by continuous innovation and competitive strategies to cater to unmet needs. A strategic focus on collaborations with tech firms to integrate AI and IoT in diabetes management systems can provide substantial business growth, enhancing patient adherence and outcomes. Exploring biosimilars and cost-effective generics can also offer significant market opportunities, especially in price-sensitive markets.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antidiabetic Drugs Market

The Antidiabetic Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetes and increasing obesity among people
    • Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
    • Initiatives and programs supporting diabetes awareness & treatment
  • Market Restraints
    • Adverse effects associated with antidiabetic drugs
  • Market Opportunities
    • Ongoing research and development for new antidiabetic drugs
    • Governments and private companies collaborations to supply inexpensive drugs
  • Market Challenges
    • Stringent regulatory requirements for the approval of antidiabetic drugs

Porter's Five Forces: A Strategic Tool for Navigating the Antidiabetic Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antidiabetic Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antidiabetic Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antidiabetic Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antidiabetic Drugs Market

A detailed market share analysis in the Antidiabetic Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antidiabetic Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antidiabetic Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antidiabetic Drugs Market

A strategic analysis of the Antidiabetic Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin is further studied across Intermediate-Acting Insulin, Long-Acting Analog, Premixed Insulin, Rapid-Acting Analog, and Short-Acting Analog.
  • Based on Disease, market is studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
  • Based on Patient, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes and increasing obesity among people
      • 5.1.1.2. Growing awareness among patients and healthcare professionals regarding the importance of diabetes management
      • 5.1.1.3. Initiatives and programs supporting diabetes awareness & treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse effects associated with antidiabetic drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development for new antidiabetic drugs
      • 5.1.3.2. Governments and private companies collaborations to supply inexpensive drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for the approval of antidiabetic drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Antidiabetic Drugs Market, by Type

  • 6.1. Introduction
  • 6.2. Alpha-Glucosidase Inhibitors
  • 6.3. Biguanides
  • 6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
  • 6.5. GLP-1 (Glucagon-like Peptide) Agonists
  • 6.6. Insulin
    • 6.6.1. Intermediate-Acting Insulin
    • 6.6.2. Long-Acting Analog
    • 6.6.3. Premixed Insulin
    • 6.6.4. Rapid-Acting Analog
    • 6.6.5. Short-Acting Analog
  • 6.7. Meglitinides
  • 6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
  • 6.9. Sulphonylureas
  • 6.10. Thiazolidinedione

7. Antidiabetic Drugs Market, by Disease

  • 7.1. Introduction
  • 7.2. Diabetes Mellitus Type 1
  • 7.3. Diabetes Mellitus Type 2

8. Antidiabetic Drugs Market, by Patient

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Americas Antidiabetic Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antidiabetic Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antidiabetic Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Alkem Laboratories Ltd.
  • 3. Aristo Pharmaceuticals Pvt. Ltd.
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Biocon Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cadila Pharmaceuticals Limited
  • 9. Cipla Limited
  • 10. Dr. Reddy's Laboratories
  • 11. Eli Lilly and Company
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Glenmark Pharmaceuticals Ltd.
  • 15. Halozyme Therapeutics, Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Mankind Pharma Ltd.
  • 18. Merck KGaA
  • 19. Novo Nordisk A/S
  • 20. Oramed Pharmaceuticals Inc.
  • 21. Pfizer Inc.
  • 22. PHC Holdings Corporation
  • 23. Sanofi S.A.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Teva Pharmaceutical Industries Ltd.
  • 26. Tonghua Dongbao Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. ANTIDIABETIC DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIDIABETIC DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANTIDIABETIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIDIABETIC DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ALPHA-GLUCOSIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-IV (DIPEPTIDYL PEPTIDASE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 (GLUCAGON-LIKE PEPTIDE) AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INTERMEDIATE-ACTING INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREMIXED INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SHORT-ACTING ANALOG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MEGLITINIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-II (SODIUM GLUCOSE TRANSPORT PROTEINS) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULPHONYLUREAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THIAZOLIDINEDIONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 1, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DIABETES MELLITUS TYPE 2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT, 2018-2030 (USD MILLION)
  • TABLE 198. ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2023